“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in USD
Last close As at 26/05/2023
USD1.45
▲ −0.09 (−5.84%)
Market capitalisation
USD92m
VolitionRx is a clinical diagnostics company developing easy-to-use and cost-effective blood tests to diagnose a range of diseases in humans and animals including sepsis and cancer. Diagnostic Nu.Q tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid.
Managing Director - Head of Content, Healthcare
Cameron Reynolds
CEO
Jake Micallef
Chief Scientific Officer
Scott Powell
Director of IR
Terig Hughes
CFO
Forecast net debt (US$m)
1.6
Forecast gearing ratio (%)
94
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (8.2) | (22.9) | (37.8) |
| Relative | (10.0) | (26.2) | (40.4) |
| 52 week high/low | US$2.7/US$1.4 |
While pets are increasingly being ‘humanized’, their healthcare has lagged advancements seen on the human side. With the COVID-19 pandemic accelerating the trend of pet ownership, demand for improved care in a market with limited alternatives has triggered the need for newer-generation pet diagnostics. VolitionRx, a diagnostics company focused on sepsis and cancer detection, has pioneered a low-cost, quick-turnaround, cancer screening and monitoring tool for companion animals (Nu.Q Vet), an adaption of its core nucleosome quantification (Nu.Q) platform on the human side. With supply and distribution deals with leading veterinary diagnostics players IDEXX and Heska already signed, Nu.Q Vet has the building blocks in place to evolve into a potential disrupter in the space.
| Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 0.0 | (17.9) | (18.0) | (57.37) | N/A | N/A |
| 2019A | 0.0 | (16.1) | (16.1) | (41.09) | N/A | N/A |
| 2020E | 0.0 | (17.2) | (17.4) | (42.61) | N/A | N/A |
| 2021E | 0.1 | (18.6) | (18.8) | (44.46) | N/A | N/A |
Managing Director - Head of Content, Healthcare
Get access to the very latest content matched to your personal investment style.
